For biotechnology and life-sciences patent practices, sequence listings can be among the most technically demanding parts of preparing a patent application. They require accurate handling of nucleotide and amino acid sequences, structured data, bibliographic information, feature annotations, and increasingly sophisticated filing standards.
Since July 1, 2022, applications filed internationally, nationally, or regionally that contain qualifying nucleotide or amino acid sequence disclosures generally fall under WIPO Standard ST.26, which replaced the previous ST.25 standard. ST.26 requires sequence listings in XML format and was designed to improve consistency, validation, searching, and interoperability between patent offices and sequence databases.
For patent attorneys, this creates an important operational question: Should sequence listing preparation be handled entirely in-house, or should it be outsourced to a specialist provider?
Outsourcing can reduce administrative workload and improve consistency, but only if the attorney’s team retains appropriate control over the underlying sequence data, disclosure, and filing strategy.
Why Sequence Listing Preparation Is Different
A sequence listing is not simply a formatted copy of sequences appearing in the specification.
Under ST.26, the listing contains structured information about individual sequences, including sequence data and associated features and qualifiers. The standard also establishes rules governing which sequences must be included and how they should be represented.
The practical consequence is that sequence-listing preparation sits at the intersection of:
- patent drafting;
- molecular biology;
- data management;
- XML formatting;
- formal patent requirements; and
- filing-office procedures.
A provider may be excellent at XML generation but still need clear instructions from patent counsel regarding the application’s disclosure and the intended filing.
That distinction is critical.
What Can Safely Be Outsourced?
Much of the technical preparation and validation can be outsourced.
A specialist provider can typically assist with:
- extracting sequences from source documents;
- organizing sequence data;
- assigning sequence identifiers;
- entering bibliographic information;
- applying appropriate ST.26 structure;
- entering feature annotations and qualifiers;
- generating the XML file;
- running validation;
- identifying formatting or data errors; and
- preparing a filing-ready deliverable.
WIPO itself provides WIPO Sequence, a desktop application intended to help applicants create and validate ST.26-compliant listings. The software can import sequence-listing files, validate XML, and generate the final sequence listing after validation.
Outsourcing therefore does not mean abandoning attorney oversight. It means transferring repetitive technical work to a specialist while retaining legal responsibility for the application strategy.
The Attorney Still Owns the Disclosure Question
One of the most important boundaries is the difference between formatting information and deciding what the patent application discloses.
A sequence-listing specialist should not independently decide that a sequence belongs in the application merely because it appears somewhere in laboratory materials. Nor should the provider add a sequence because it appears scientifically relevant.
The attorney and applicant must establish what is actually part of the patent disclosure.
This matters particularly when sequence data appear in multiple versions:
- experimental reports;
- laboratory notebooks;
- draft specifications;
- inventor spreadsheets;
- sequence-analysis software;
- earlier patent applications; and
- priority documents.
The sequence listing must accurately reflect the application to which it belongs.
For PCT applications, WIPO states that a subsequently furnished ST.26 sequence listing must not go beyond the disclosure in the international application as filed when it is being provided for search purposes under Rule 13ter.
That makes source-control essential.
Start With a Controlled Source File
Before outsourcing the work, the patent team should identify the authoritative source material.
Ideally, the project should specify:
Which document contains the approved sequences?
The answer might be:
- the final patent specification;
- an inventor-approved sequence table;
- a validated laboratory data set; or
- a combination of controlled source documents.
The provider should not be expected to determine which of several conflicting versions represents the final disclosure.
For example, if an inventor has supplied three versions of SEQ ID NO: 15, the provider can identify the discrepancy—but the patent team should determine which sequence is legally intended for the application.
Sequence Numbering Requires Particular Care
Sequence identifiers are more than formatting labels.
If the specification refers to SEQ ID NO: 1 as one sequence and the listing identifies a different sequence as SEQ ID NO: 1, the resulting inconsistency can create significant problems.
A quality-control process should therefore verify that:
- every sequence referenced in the specification appears correctly in the listing;
- every sequence identifier is unique;
- sequence numbers correspond to the intended sequences;
- sequences are not accidentally reordered;
- deleted or amended sequences are properly handled; and
- references in the description and claims remain consistent.
This is an area where outsourcing can be particularly valuable because specialist providers can use dedicated workflows and validation tools—but the attorney should still review the final mapping.
ST.26 Is More Than Converting TXT to XML
One of the biggest misconceptions about sequence-listing outsourcing is that ST.26 preparation is essentially a file-conversion exercise.
It is not.
ST.26 uses structured XML and incorporates specific rules concerning sequence representation and associated information. WIPO notes that ST.26 accommodates sequence types that were not adequately covered under the previous ST.25 framework, including D-amino acids, nucleotide analogs, and certain branched sequences. It also changed the treatment of small sequences.
The conversion from an older ST.25 listing therefore cannot always be treated as a mechanical transformation.
WIPO’s current tools can import ST.25/ST.26 files, but the resulting project still needs to be checked and validated.
Validation Should Be a Separate Quality-Control Step
A professional outsourcing workflow should include formal validation before delivery.
WIPO Sequence validates ST.26 XML against the applicable DTD and business rules. WIPO also explains that patent offices may use the WIPO Sequence Validator or equivalent validation mechanisms.
The provider should therefore deliver more than an XML file.
Ideally, the attorney should receive:
- the final ST.26 XML file;
- a validation report or confirmation;
- a human-readable representation for review;
- a sequence-number cross-check;
- a record of source files used; and
- a list of unresolved questions or assumptions, if any.
This creates an audit trail that can be particularly valuable when an application contains hundreds or thousands of sequences.
Human-Readable Review Still Matters
XML validation does not guarantee substantive accuracy.
A sequence listing can be technically valid XML while containing the wrong sequence, incorrect annotation, or incorrect bibliographic information.
That is why attorneys should not rely solely on a message saying:
“The file passed validation.”
Validation confirms compliance with specified technical rules. It does not necessarily confirm that the listing accurately reflects the inventor’s intended disclosure.
WIPO’s documentation itself distinguishes between validation and the underlying sequence information. WIPO Sequence is designed to validate the listing’s structure and compliance, but the underlying project data still need to be correct.
A human-readable review therefore remains an important part of the process.
Bibliographic Information Needs Attention
ST.26 listings also contain bibliographic information used to associate the listing with the patent application.
WIPO explains that the required bibliographic information is defined in ST.26 and can include applicant and application-related information, with particular requirements depending on whether priority is claimed and when the listing is prepared.
When outsourcing, the attorney should provide controlled instructions for:
- applicant name;
- invention title;
- application or reference information;
- priority information;
- relevant dates; and
- language information.
The provider should not guess missing bibliographic data.
A wrong applicant name or priority reference can be more than a cosmetic error.
Confidentiality Is a Major Outsourcing Issue
Sequence data can contain commercially sensitive research information, unpublished inventions, proprietary constructs, and other confidential material.
Before sending sequence data to an external provider, the patent firm should evaluate:
- confidentiality agreements;
- data-processing arrangements;
- security controls;
- access restrictions;
- storage locations;
- subcontractors;
- employee access;
- retention periods; and
- deletion procedures.
If the provider uses cloud-based software or automated processing, the attorney should understand where the data are stored and who can access them.
This is particularly important for unpublished applications and inventions approaching a filing deadline.
Data Security Should Be Part of Vendor Selection
A low-cost provider is not necessarily a low-risk provider.
Patent firms should ask prospective vendors whether they have documented procedures for:
- secure file transfer;
- encryption;
- access control;
- authentication;
- backups;
- incident response;
- employee confidentiality;
- data deletion; and
- business continuity.
The provider should also be able to explain whether client files are retained after project completion and whether they are used for any secondary purpose.
For sensitive biotechnology work, these questions should be addressed before the first sequence file is transmitted.
Turnaround Time Matters—but Accuracy Matters More
Sequence-listing projects often arise close to filing deadlines.
That makes turnaround time an important outsourcing consideration, but speed should not become the primary performance metric.
A provider that delivers a sequence listing in several hours but requires extensive attorney correction may create more risk than a provider that takes slightly longer but delivers a thoroughly checked file.
A useful service-level framework might measure:
- initial turnaround time;
- revision turnaround;
- validation success rate;
- error rate;
- number of attorney corrections;
- response time to questions; and
- deadline performance.
The best vendor relationship should make the patent team’s workflow more predictable, not simply faster.
Establish a Clear Responsibility Matrix
Before outsourcing, define who is responsible for each part of the process.
For example:
| Task | Patent Team | Outsourcing Provider |
| Identify relevant disclosure | Primary | Support |
| Select authoritative source data | Primary | — |
| Interpret technical ambiguity | Primary / inventor | Support |
| Enter sequence data | Review | Primary |
| Generate ST.26 XML | Review | Primary |
| Technical validation | Review | Primary |
| Confirm sequence identity | Primary | Support |
| Confirm bibliographic information | Primary | Support |
| Final filing decision | Primary | — |
This prevents the common problem of assumed responsibility.
The provider should know when to stop and ask a question rather than making an unsupported assumption.
Build an Exception-Handling Process
The strongest outsourcing workflows are designed around exceptions.
A provider should flag issues such as:
- duplicate sequence identifiers;
- inconsistent sequence lengths;
- conflicting sequence versions;
- missing annotations;
- unclear organism information;
- uncertain molecule type;
- ambiguous feature locations;
- discrepancies between the sequence listing and specification; or
- missing bibliographic information.
The provider should not silently resolve material discrepancies.
Instead, establish a standard query format:
Issue → affected sequence → source discrepancy → proposed options → attorney decision
This makes review much faster and creates a defensible record.
International Filing Requires Extra Planning
ST.26 is intended to provide a common framework across international, regional, and national procedures, but individual filing systems and procedural requirements can still differ.
For PCT applications, the sequence listing forms part of the description when filed in the required ST.26 format. WIPO’s PCT Receiving Office Guidelines state that sequence listings must comply with ST.26 and be filed in XML format.
WIPO’s Administrative Instructions further state that an international application containing a qualifying sequence listing should present it as an XML file and strongly recommends using WIPO Sequence or equivalent software capable of validating the listing.
The attorney should therefore confirm the filing requirements for the relevant receiving office and subsequent national or regional procedures rather than assuming that one technical workflow will cover every procedural issue.
Watch the ST.26 Version
ST.26 is not static.
WIPO currently lists ST.26 Version 1.7, issued in November 2025, and indicates that Version 2.0 enters into force on July 1, 2027.
This is particularly relevant when outsourcing because a vendor’s software and internal procedures need to remain aligned with the applicable version.
Patent firms should ask providers:
- Which ST.26 version does your workflow support?
- When was your validation software last updated?
- How do you handle standards changes?
- Who monitors WIPO updates?
- How are existing client templates migrated?
- What happens to projects spanning a standards transition?
A provider should have a documented update process rather than waiting until a filing fails validation.
Avoid Creating a Single Point of Failure
Outsourcing should not mean that only one person at the vendor understands the client’s workflow.
Ask whether the provider has:
- multiple trained specialists;
- documented procedures;
- backup personnel;
- quality-control reviewers;
- business continuity plans; and
- secure project records.
This becomes especially important for patent firms handling large portfolios.
If a single specialist is unavailable immediately before a major filing deadline, the firm’s entire process should not depend on that individual’s memory.
What a Good Outsourcing Checklist Looks Like
Before sending a sequence-listing project to an external provider, the patent team should confirm:
- the applicable ST.26 requirements;
- the filing jurisdiction and deadline;
- the authoritative source documents;
- the expected sequence count;
- sequence numbering requirements;
- applicant and bibliographic information;
- priority information;
- confidentiality arrangements;
- secure file-transfer procedures;
- required validation;
- attorney review responsibilities; and
- final delivery format.
The provider should also know who to contact when an ambiguity arises.
Outsourcing Does Not Transfer Legal Responsibility
Perhaps the most important principle is simple:
Outsourcing preparation does not outsource legal judgment.
The external provider can prepare, structure, validate, and quality-check the sequence listing. But the patent attorney remains responsible for ensuring that the filing accurately represents the application and complies with the relevant legal and procedural requirements.
This is particularly important where a sequence listing could affect the substantive disclosure of the invention.
The attorney should therefore treat the provider as a specialized technical partner—not as the final decision-maker regarding patent scope or disclosure.
The Best Model: Specialist Preparation + Attorney Control
For many patent practices, the most effective model is a controlled division of responsibilities.
The provider handles the labor-intensive technical work:
- sequence extraction;
- data entry;
- XML generation;
- formatting;
- validation; and
- preliminary quality control.
The patent team retains control over:
- the authoritative disclosure;
- sequence identity;
- claim relevance;
- substantive corrections;
- bibliographic accuracy;
- filing strategy; and
- final approval.
This approach can substantially reduce repetitive work while preserving the attorney’s oversight of issues that can affect the patent application itself.
Final Takeaway
Outsourcing sequence listing preparation can be a highly effective way for patent practices to manage biotechnology filings, particularly where applications contain large numbers of sequences or require complex ST.26 annotations.
But successful outsourcing depends on more than finding a provider that can generate an XML file.
Patent attorneys should establish a controlled workflow based on authoritative source data, clear responsibility boundaries, confidentiality safeguards, technical validation, substantive review, and documented exception handling.
The goal should be straightforward:
Let specialists handle the technical complexity while keeping the patent team firmly in control of the disclosure and filing.
With that structure in place, outsourcing can turn sequence-listing preparation from a deadline-driven administrative burden into a predictable, quality-controlled part of the patent prosecution workflow.